Danaher Co. (NYSE:DHR) Shares Sold by Manchester Global Management UK Ltd

Manchester Global Management UK Ltd lowered its position in Danaher Co. (NYSE:DHR) by 7.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 150,688 shares of the conglomerate’s stock after selling 11,500 shares during the quarter. Danaher accounts for approximately 6.6% of Manchester Global Management UK Ltd’s investment portfolio, making the stock its 4th largest position. Manchester Global Management UK Ltd’s holdings in Danaher were worth $37,649,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. Cape Investment Advisory Inc. acquired a new position in shares of Danaher in the fourth quarter valued at approximately $25,000. Tsfg LLC boosted its holdings in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC bought a new stake in Danaher in the second quarter valued at approximately $25,000. Finally, Redmont Wealth Advisors LLC bought a new stake in Danaher in the first quarter valued at approximately $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the transaction, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by company insiders.

Danaher Trading Up 0.2 %

Shares of Danaher stock opened at $273.19 on Tuesday. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The firm has a market cap of $202.35 billion, a PE ratio of 46.30, a P/E/G ratio of 4.48 and a beta of 0.83. The stock has a fifty day moving average price of $268.16 and a 200-day moving average price of $257.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s revenue was down 2.9% compared to the same quarter last year. During the same period last year, the firm posted $2.05 EPS. Equities research analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on DHR shares. Robert W. Baird upped their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Barclays increased their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Evercore ISI cut their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.